Skip to main content


Alpha-glucosidase inhibitors

01-31-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

05-08-2018 | Pregnancy | Review | Article

Pharmacotherapy for hyperglycemia in pregnancy: Do oral agents have a place?

Corcoy R et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.04.015

01-04-2018 | Medication adherence | Article

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study

McGovern A et al. Diabetes Ther 2018; 9: 229–242. doi: 10.1007/s13300-017-0361-5

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

07-31-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Xu J, Rajaratnam R. Cardiovasc Diabetol 2017; 16: 18. doi: 10.1186/s12933-017-0499-5

Image Credits